256 related articles for article (PubMed ID: 9371578)
1. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.
Schreiber M; Wachsmuth C; Müller H; Odemuyiwa S; Schmitz H; Meyer S; Meyer B; Schneider-Mergener J
J Virol; 1997 Dec; 71(12):9198-205. PubMed ID: 9371578
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
Moore JP; Ho DD
J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
[TBL] [Abstract][Full Text] [Related]
3. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
4. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
[TBL] [Abstract][Full Text] [Related]
5. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.
Schreiber M; Petersen H; Wachsmuth C; Müller H; Hufert FT; Schmitz H
J Virol; 1994 Jun; 68(6):3908-16. PubMed ID: 8189527
[TBL] [Abstract][Full Text] [Related]
6. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
7. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
8. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression.
Schreiber M; Wachsmuth C; Müller H; Hagen C; Schmitz H; van Lunzen J
J Gen Virol; 1996 Oct; 77 ( Pt 10)():2403-14. PubMed ID: 8887471
[TBL] [Abstract][Full Text] [Related]
9. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120.
Schønning K; Bolmstedt A; Novotny J; Lund OS; Olofsson S; Hansen JE
AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1451-6. PubMed ID: 9824323
[TBL] [Abstract][Full Text] [Related]
10. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
11. Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1.
Aguilar A; Carrazana Y; Duarte CA
Biomol Eng; 2001 Oct; 18(3):117-24. PubMed ID: 11566603
[TBL] [Abstract][Full Text] [Related]
12. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
13. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
[TBL] [Abstract][Full Text] [Related]
14. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
[TBL] [Abstract][Full Text] [Related]
15. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
[TBL] [Abstract][Full Text] [Related]
16. V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.
Schiappacassi M; Buratti E; D'Agaro P; Ciani L; Scodeller ES; Tisminetzky SG; Baralle FE
J Virol Methods; 1997 Jan; 63(1-2):121-7. PubMed ID: 9015282
[TBL] [Abstract][Full Text] [Related]
17. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.
Huisman JG; Carotenuto A; Labrijn AF; Papavoine CH; Laman JD; Schellekens MM; Koppelman MH; Hilbers CW
Biochemistry; 2000 Sep; 39(35):10866-76. PubMed ID: 10978173
[TBL] [Abstract][Full Text] [Related]
18. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
[TBL] [Abstract][Full Text] [Related]
19. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
20. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
